Correlation Between Karyopharm Therapeutics and DiaMedica Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Karyopharm Therapeutics and DiaMedica Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Karyopharm Therapeutics and DiaMedica Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Karyopharm Therapeutics and DiaMedica Therapeutics, you can compare the effects of market volatilities on Karyopharm Therapeutics and DiaMedica Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Karyopharm Therapeutics with a short position of DiaMedica Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Karyopharm Therapeutics and DiaMedica Therapeutics.

Diversification Opportunities for Karyopharm Therapeutics and DiaMedica Therapeutics

-0.44
  Correlation Coefficient

Very good diversification

The 3 months correlation between Karyopharm and DiaMedica is -0.44. Overlapping area represents the amount of risk that can be diversified away by holding Karyopharm Therapeutics and DiaMedica Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on DiaMedica Therapeutics and Karyopharm Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Karyopharm Therapeutics are associated (or correlated) with DiaMedica Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of DiaMedica Therapeutics has no effect on the direction of Karyopharm Therapeutics i.e., Karyopharm Therapeutics and DiaMedica Therapeutics go up and down completely randomly.

Pair Corralation between Karyopharm Therapeutics and DiaMedica Therapeutics

Given the investment horizon of 90 days Karyopharm Therapeutics is expected to under-perform the DiaMedica Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Karyopharm Therapeutics is 4.05 times less risky than DiaMedica Therapeutics. The stock trades about -0.71 of its potential returns per unit of risk. The DiaMedica Therapeutics is currently generating about 0.11 of returns per unit of risk over similar time horizon. If you would invest  462.00  in DiaMedica Therapeutics on September 26, 2024 and sell it today you would earn a total of  64.00  from holding DiaMedica Therapeutics or generate 13.85% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Karyopharm Therapeutics  vs.  DiaMedica Therapeutics

 Performance 
       Timeline  
Karyopharm Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Karyopharm Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain strong and the recent confusion on Wall Street may also be a sign of long-lasting gains for the firm traders.
DiaMedica Therapeutics 

Risk-Adjusted Performance

6 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in DiaMedica Therapeutics are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of rather unsteady basic indicators, DiaMedica Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point.

Karyopharm Therapeutics and DiaMedica Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Karyopharm Therapeutics and DiaMedica Therapeutics

The main advantage of trading using opposite Karyopharm Therapeutics and DiaMedica Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Karyopharm Therapeutics position performs unexpectedly, DiaMedica Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DiaMedica Therapeutics will offset losses from the drop in DiaMedica Therapeutics' long position.
The idea behind Karyopharm Therapeutics and DiaMedica Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Other Complementary Tools

AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios